In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Bradley Monk to discuss ctDNA: Results from CALLA Trial.   Bradley Monk, MD, FACOG, FACS is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute and medical director of the Late-Stage Clinical Research Program. He provides care to patients at the FCS West Palm Beach location.Dr. Monk has extensive leadership experience in practice-changing clinical research and the development of clinical research programs in community oncology settings. His research special interests are primarily focused on the prevention and treatment of gynecologic cancers. As a principal investigator, Dr. Monk has been involved in numerous groundbreaking studies throughout his career.Dr. Monk is a co-founder of the GOG-Partners (GOG-P) Foundation® (GOG-F), a nonprofit organization committed to advancing clinical and scientific research in the field of gynecologic malignancies. The organization was instrumental in establishing a national gynecologic clinical trials network. He has presented his findings at hundreds of national and international forums and authored more than 400 peer-reviewed articles and more than 35 book chapters focused on the prevention and treatment of gynecologic malignancies and patient reported outcomes. Dr. Monk is a past recipient of the esteemed Ernst Wertheim Award for his research in cervical cancer.Prior to joining FCS in 2024, Dr. Monk served as director and principal investigator for HonorHealth at the Virginia G. Piper Cancer Center in Scottsdale, Arizona, where he also served as the site research leader for Sarah Cannon Research Institute. Among his numerous academic appointments, he most recently served as a professor on the Clinical Scholar Track at the University of Arizona College of Medicine.